Excerpt | Relevance | Reference |
"BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under clinical development for cancer therapy." | 5.36 | The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. ( de Boer, RA; Lu, B; Maass, AH; Mahmud, H; Silljé, HH; van Gilst, WH; Yu, B, 2010) |
"BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under clinical development for cancer therapy." | 1.36 | The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. ( de Boer, RA; Lu, B; Maass, AH; Mahmud, H; Silljé, HH; van Gilst, WH; Yu, B, 2010) |